---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Care management intervention strategies"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Care management intervention strategies. Topics: ESMO recommendation for ESR1 testing after progression on an aromatase inhibitor, ABC8 consensus on ctDNA testing at each progression and retesting, ABC8 consensus against ctDNA as a test of disease progression, Liquid biopsy for acquired alterations in second and later lines, and 9 further topics. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### ESMO recommendation for ESR1 testing after progression on an aromatase inhibitor

> “Evaluation of ESR1 mutations [circulating tumour DNA (ctDNA) or tumour tissue] is recommended in ER-positive, HER2-negative MBC following progression on an aromatase inhibitor (AI) with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [I, A; ESCAT score: I-A].”
> “Evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway alterations (PIK3CA, PTEN and AKT1 mutations) using ctDNA or metastatic or primary tumour biopsies is recommended in ER-positive, HER2-negative MBC, mainly in the endocrine-resistant setting, if specific treatments are available [I, A; ESCAT score: I-A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.4-2"></a>

### ABC8 consensus on ctDNA testing at each progression and retesting

> “The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.”
> “The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound and consistent with both regulatory developments and real-world clinic-genomic data”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.4-3"></a>

### ABC8 consensus against ctDNA as a test of disease progression

> “We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.4-4"></a>

### Liquid biopsy for acquired alterations in second and later lines

> “Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines. Reflex TBx should be considered when ctDNA TF < 1%.”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.2.4-5"></a>

### ESMO guideline interval for response assessment

> “Evaluation of response can be recommended every 2-4 months depending on patient symptoms, disease dynamics, location, extent of metastasis and type of treatment [V, B].”
> “Shortening of disease monitoring intervals cannot be recommended as there is no evidence of an overall survival benefit and there is potential for emotional and financial harm [IV, D].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.4-6"></a>

### Managed care practices for ESR1 testing and ctDNA monitoring

> “A primary consideration of payers related to aBC is that the optimal biomarker testing parameters, including ctDNA-based monitoring for ESR1m aBC, are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care.”
> “Key insights include that community oncologists and patients may benefit from support, for example, with treatment pathways and patient navigators.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)

<a id="topic-2.2.2.4-7"></a>

### Prior authorization practices suggested by managed care stakeholders

> “They also indicated that many payers are already working to reduce prior authorization burden through practices such as auto-approvals (eg, for requests in concordance with biomarker testing guidelines), extending authorization duration (eg, from 12 to 24 months), and allowing gold carding, which relaxes prior authorization requirements for providers who have a demonstrated history of complying with coverage criteria.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)

<a id="topic-2.2.2.4-8"></a>

### ASCO and ONS safety standards for oral antineoplastic therapy

> “A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy.”
> “The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home.”

Source: [Neuss et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27868581/)

<a id="topic-2.2.2.4-9"></a>

### ASCO and ONS 2024 standards update including home administration

> “The standards presented here include clarification and expansion of existing standards to include home administration and other changes in processes of ordering, preparing, and administering antineoplastic therapy; the advent of immune effector cellular therapy; the importance of social determinants of health; fertility preservation; and pregnancy avoidance.”

Source: [Siegel et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38776491/)

<a id="topic-2.2.2.4-10"></a>

### Adherence to oral anticancer therapy with a smartphone application (randomized trial)

> “Study groups did not differ across any outcome measure, with an overall mean adherence of 78.81% (SD, 26.66%) per electronic pill caps.”
> “Although the mobile app may not improve outcomes for all patients prescribed oral cancer therapy, the intervention may be beneficial for those with certain risk factors, such as difficulties with adherence or anxiety.”

Source: [Greer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32023526/)

<a id="topic-2.2.2.4-11"></a>

### Adherence interventions for oral therapy in breast cancer (systematic review)

> “Thirty-six studies met the inclusion criteria and involved a total sample of 28,528 BC patients.”
> “The use of reminders, monitoring patients' medication-taking behaviors and giving feedback were the most frequently implemented techniques in those interventions that resulted significant.”

Source: [Pezzolato et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37571974/)

<a id="topic-2.2.2.4-12"></a>

### CMS Enhancing Oncology Model scope for breast cancer

> “Unlike OCM, EOM focuses on beneficiaries receiving systemic initiating cancer therapy, and will not include beneficiaries who receive hormonal therapy only.”
> “Subject to certain exceptions, EOM includes the following seven cancer types for beneficiaries undergoing systemic initiating cancer therapy: high-risk breast cancer, chronic leukemia, small intestine/colorectal cancer, lung cancer, lymphoma, multiple myeloma, and high-intensity prostate cancer.”

Source: [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)

<a id="topic-2.2.2.4-13"></a>

### CMS Enhancing Oncology Model care redesign activities

> “The eight EOM PRAs are: Provide beneficiaries 24/7 access to an appropriate clinician with real-time access to the EOM participant’s medical records; Provide patient navigation, as appropriate, to EOM beneficiaries; Document a care plan for each EOM beneficiary that contains the 13 components of the Institute of Medicine (IOM) Care Management Plan, as applicable to the EOM beneficiary; Treat beneficiaries with therapies in a manner consistent with nationally recognized clinical guidelines; Identify EOM beneficiary health-related social needs using a health-related social needs screening (HRSN) tool; Collect and monitor electronic Patient Reported Outcomes (ePROs); Utilize data for continuous quality improvement (CQI); and Use Certified EHR Technology (CEHRT) as specified in 42 CFR § 414.1415(a).”

Source: [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)

Additional sources: [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
